126 related articles for article (PubMed ID: 37199288)
1. Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
Haroun EA; Mansour NO; Eltantawy A; Shams MEE
Pharmacotherapy; 2023 Sep; 43(9):872-882. PubMed ID: 37199288
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial.
Bakry HM; Mansour NO; ElKhodary TR; Soliman MM
Front Pharmacol; 2023; 14():1181312. PubMed ID: 37583905
[No Abstract] [Full Text] [Related]
4. Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Shigematsu H; Hirata T; Nishina M; Yasui D; Ozaki S
Support Care Cancer; 2020 Oct; 28(10):5005-5011. PubMed ID: 32036471
[TBL] [Abstract][Full Text] [Related]
5. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
Koyanagi M; Imai S; Iwamitsu Y; Matsumoto M; Saigo M; Moriya A; Ogihara T; Nakazato Y; Yonezawa A; Nakagawa S; Nakagawa T; Matsubara K
Neuropharmacology; 2021 May; 188():108514. PubMed ID: 33684416
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
8. Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB
Oncologist; 2021 May; 26(5):366-374. PubMed ID: 33523545
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
[TBL] [Abstract][Full Text] [Related]
10. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
Kanbayashi Y; Sakaguchi K; Ishikawa T; Ouchi Y; Nakatsukasa K; Tabuchi Y; Kanehisa F; Hiramatsu M; Takagi R; Yokota I; Katoh N; Taguchi T
Breast; 2020 Feb; 49():219-224. PubMed ID: 31901783
[TBL] [Abstract][Full Text] [Related]
13. Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.
Zirpoli GR; McCann SE; Sucheston-Campbell LE; Hershman DL; Ciupak G; Davis W; Unger JM; Moore HCF; Stewart JA; Isaacs C; Hobday TJ; Salim M; Hortobagyi GN; Gralow JR; Budd GT; Albain KS; Ambrosone CB
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546345
[TBL] [Abstract][Full Text] [Related]
14. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
[TBL] [Abstract][Full Text] [Related]
16. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
17. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Werida RH; Elshafiey RA; Ghoneim A; Elzawawy S; Mostafa TM
Support Care Cancer; 2022 Sep; 30(9):7281-7292. PubMed ID: 35596774
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Aghili M; Zare M; Mousavi N; Ghalehtaki R; Sotoudeh S; Kalaghchi B; Akrami S; Esmati E
Breast J; 2019 Mar; 25(2):226-231. PubMed ID: 30773731
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel.
Pandey P; Kumar A; Pushpam D; Khurana S; Malik PS; Gogia A; Arunmozhimaran E; Singh MB; Chandran DS; Batra A
Trials; 2023 Feb; 24(1):79. PubMed ID: 36732774
[TBL] [Abstract][Full Text] [Related]
20. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
